Consensus Pulmonx Corporation

Stocks

LUNG

US7458481014

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 00:00:00 01/10/2026 +04			5-day change	1st Jan Change
1.910 ^USD	-3.54%		-4.50%	-13.57%

07-30	Pulmonx Corporation, Q2 2026 Earnings Call, Jul 29, 2026
07-30	Pulmonx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Pulmonx Corporation

Evolution of the Target Price: Pulmonx Corporation

Changes in Analyst Recommendations: Pulmonx Corporation

8e85c8c3560f48.jZyAw69pGPf1njYhTtJrtWq0-gmbwL7tUI4vzUoWs-Q.6drRpeYTSYSd7EAQLJMimDLez1CtrduHG-9igzMg64_X3fiCnhldspymBg~356ccfa48c4cdaf1c891d02528b126d8

Analysts' recommendations: Pulmonx Corporation

31/07/25	Piper Sandler Downgrades Pulmonx to Neutral From Overweight, Adjusts Price Target to $2.50 From $9	MT
31/07/25	Pulmonx Q2 revenue up 15%, beats expectations, cuts FY revenue forecast	RE
11/12/24	Citigroup Downgrades Pulmonx to Neutral From Buy, Cuts Price Target to $7.50 From $17	MT
04/06/24	Lake Street Initiates Pulmonx With Buy Rating, $12 Price Target	MT
23/02/24	Wells Fargo Downgrades Pulmonx to Equalweight From Overweight, Cuts Price Target to $14 From $16	MT
22/02/24	Craig-Hallum Adjusts Pulmonx's Price Target to $20 From $18, Keeps Buy Rating	MT
22/02/24	Citigroup Adjusts Pulmonx's Price Target to $17 From $16, Keeps Buy Rating	MT
22/02/24	Wells Fargo Adjusts Pulmonx's Price Target to $16 From $15, Keeps Overweight Rating	MT
22/02/24	Stifel Adjusts Pulmonx's Price Target to $17 From $15, Keeps Buy Rating	MT
22/02/24	Canaccord Genuity Adjusts Pulmonx's Price Target to $16 From $12, Keeps Buy Rating	MT
05/09/23	Craig-Hallum Initiates Pulmonx at Buy With $18 Price Target	MT
11/07/23	Citigroup Raises Price Target on Pulmonx to $16 From $14, Maintains Buy Rating	MT
03/05/23	Piper Sandler Adjusts Pulmonx's Price Target top $15 From $13, Keeps Overweight Rating	MT
03/05/23	Morgan Stanley Adjusts Pulmonx's Price Target to $14 From $11, Keeps Equalweight Rating	MT
03/04/23	Citigroup Adjusts Pulmonx Price Target to $13 From $12, Maintains Buy Rating	MT
27/02/23	Wells Fargo Upgrades Pulmonx to Overweight From Equalweight, Adjusts Price Target to $15 From $10	MT
23/02/23	Morgan Stanley Adjusts Price Target on Pulmonx to $11 From $9.50, Keeps Equalweight Rating	MT
23/02/23	Canaccord Genuity Adjusts Price Target on Pulmonx to $20 From $18, Maintains Buy Rating	MT
06/01/23	Morgan Stanley Adjusts Price Target on Pulmonx to $9.50 From $14, Maintains Equalweight Rating	MT
03/01/23	BofA Securities Downgrades Pulmonx to Underperform From Neutral With $8 Price Target	MT
12/12/22	Wells Fargo Cuts Price Target on Pulmonx to $6 From $13.50, Maintains Equalweight Rating	MT
12/12/22	Citigroup Upgrades Pulmonx to Buy From Neutral, Adjusts Price Target to $10 From $14	MT
07/11/22	Morgan Stanley Adjusts Price Target on Pulmonx to $14 From $19, Maintains Equal-Weight Rating	MT
04/11/22	Piper Sandler Adjusts Price Target on Pulmonx to $13 From $25, Maintains Overweight Rating	MT
11/10/22	Morgan Stanley Adjusts Pulmonx's Price Target to $19 from $21, Reiterates Equalweight Rating	MT

More recommendations

Medical Equipment

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PULMONX CORPORATION					+78.01%
	ABBOTT LABORATORIES					+21.69%
	MEDTRONIC PLC					+21.49%
	STRYKER CORPORATION					+33.56%
	ESSILORLUXOTTICA					+59.76%
	CENCORA, INC.					+22.98%
	BECTON, DICKINSON AND COMPANY					+9.31%
	HOYA CORPORATION					+28.07%
	IDEXX LABORATORIES, INC.					+34.31%
	DEXCOM, INC.					+9.49%
	Average					+31.87%
	Weighted average by Cap.					+27.52%